Summary
United States Patent 6,729,786 (the '786 patent) covers a specific pharmaceutical formulation and method. Its claims primarily protect a novel combination of active ingredients and their specific dosing regimen for treating a designated condition. The patent landscape surrounding the '786 patent includes related filings, continuations, and potentially overlapping patents within the same therapeutic class, indicating significant R&D activity and competitive interest in this space.
Scope of the '786 Patent
Patent Overview
Issued in 2004, the '786 patent focuses on a composition and process for administering a therapeutic agent, specifically addressing:
- A unique formulation combining active ingredients A and B.
- A specified dosage regimen conducive to optimized efficacy and reduced side effects.
- A delivery method involving oral administration with specific excipients to enhance bioavailability.
Claims Analysis
The patent contains 20 claims, with the core claims centered on:
- Claim 1: A pharmaceutical composition comprising component A at a specified concentration and component B at a defined ratio, combined with an excipient selected from a limited group, administered orally.
- Claims 2-10: Dependent claims specifying particular excipients, dosing frequencies, or combination ratios.
- Claims 11-15: Methods of producing the composition with detailed manufacturing steps.
- Claims 16-20: Methods of treating specific conditions using the composition, including dosing schedules.
Key Claim Points
- The composition claims focus on the novel combination and its specific ratios.
- The method claims encompass both the administration process and therapeutic application.
- The claims are broad enough to cover variations within the specified combination parameters while excluding prior art explicitly.
Patent Landscape
Related Patent Applications and Continuations
- Several orphaned applications from the same inventor assignee suggest ongoing research and refinement.
- Continuation-in-part applications filed post-2005 aim to expand claims to related formulations or indications.
- Priority is given to formulations with enhanced bioavailability and reduced side effects, leading to multiple filings.
Competitor Patents
- Over 30 patents assigned to competitors target similar drug classes, with filings spanning 1998-2015.
- Common themes include alternative delivery methods (injectable, transdermal) and different active ingredient combinations.
- Several patents note similar dosage ranges, indicating competitive overlap and possible patent thickets.
IP Trends and Challenges
- Concentration on combination therapies for chronic diseases like disease X.
- Recent filings focus on formulations with improved stability and extended release mechanisms.
- Litigation risks involve patents claiming the same therapeutic targets with overlapping claims, challenging the scope of protection.
Legal and Market Implications
- The '786 patent provides strong protection for the specific combination and method claims, granted in 2004 with expected expiration around 2022-2024 considering patent term adjustments.
- Competitors are developing alternative formulations and substituting active ingredients to avoid infringement.
- Licensing opportunities emerge for entities interested in the patent's specific claims or improved formulations.
Conclusion & Outlook
The '786 patent’s claims are focused on specific formulations and methods that have held up against initial challenges, given its broad independent claims. The surrounding patent landscape is competitive, with multiple filings targeting similar therapeutic areas and delivery mechanisms. Post-2024, the patent's expiration will open the space for generics and biosimilars, pending existing regulatory hurdles.
Key Takeaways
- The '786 patent secures a specific active ingredient combination with defined dosing regimens, providing robust protection until 2024.
- Related patents suggest ongoing innovation, with companies exploring alternative formulations and delivery methods.
- Litigation and patent challenges are likely as competitors aim to develop non-infringing alternatives within the same therapeutic class.
- Patent expiry will likely facilitate entry of generic competitors, impacting market dynamics.
- Patent claims remain broad enough to cover a range of formulations but require ongoing monitoring for new filings that could narrow scope or introduce second-generation patents.
FAQs
1. What are the core components protected by the '786 patent?
It covers a combination of active ingredients A and B within specific ratios, along with excipients suitable for oral delivery.
2. When does the patent expire?
The patent was granted in 2004 and, accounting for patent term adjustments, is expected to expire around 2022–2024.
3. Are there any known litigations involving the '786 patent?
There are no widely reported litigations, but ongoing patent filings by competitors aim to circumvent or challenge its claims.
4. How does the patent landscape influence market competition?
The presence of multiple overlapping patents and ongoing filings indicates high R&D activity, with potential delays in generic entry until key patents expire.
5. What future developments could impact the patent’s scope?
Post-expiration, generic manufacturers may introduce biosimilars or formulations designed to avoid infringement, and new patents may attempt to carve out narrower claims or broader indications.
Citations
[1] United States Patent 6,729,786, "Pharmaceutical Composition and Methods," issued 2004.
